61 related articles for article (PubMed ID: 34732370)
1. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
2. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.
Rossi S; Tatangelo V; Dichiara M; Butini S; Gemma S; Brogi S; Pasquini S; Cappello M; Vincenzi F; Varani K; Lopresti L; Malchiodi M; Carrara C; Gozzetti A; Bocchia M; Marotta G; Patrussi L; Carullo G; Baldari CT; Campiani G
Biomed Pharmacother; 2024 May; 174():116537. PubMed ID: 38579402
[TBL] [Abstract][Full Text] [Related]
3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
4. PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
Carter MJ; Cox KL; Blakemore SJ; Turaj AH; Oldham RJ; Dahal LN; Tannheimer S; Forconi F; Packham G; Cragg MS
Leukemia; 2017 Jun; 31(6):1423-1433. PubMed ID: 27843137
[TBL] [Abstract][Full Text] [Related]
5. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
6. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
7. p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L; Capitani N; Tatangelo V; Tangredi C; Boncompagni G; Frezzato F; Visentin A; Marotta G; Ciofini S; Gozzetti A; Bocchia M; Trentin L; Baldari CT; Patrussi L
Front Cell Dev Biol; 2024; 12():1297116. PubMed ID: 38389706
[No Abstract] [Full Text] [Related]
8. p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB.
Tatangelo V; Boncompagni G; Capitani N; Lopresti L; Manganaro N; Frezzato F; Visentin A; Trentin L; Baldari CT; Patrussi L
Front Oncol; 2022; 12():877495. PubMed ID: 35847884
[TBL] [Abstract][Full Text] [Related]
9. Loss of AID exacerbates the malignant progression of CLL.
Lee AC; Pingali SR; Pinilla-Ibarz JA; Atchison ML; Koumenis C; Argon Y; Thomas-Tikhonenko A; De Trez C; Hu CA; Tang CA
Leukemia; 2022 Oct; 36(10):2430-2442. PubMed ID: 36042317
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
[TBL] [Abstract][Full Text] [Related]
12. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.
Baldoni S; Del Papa B; Dorillo E; Aureli P; De Falco F; Rompietti C; Sorcini D; Varasano E; Cecchini D; Zei T; Di Tommaso A; Rosati E; Alexe G; Roti G; Stegmaier K; Di Ianni M; Falzetti F; Sportoletti P
Int J Cancer; 2018 Aug; 143(4):958-970. PubMed ID: 29508386
[TBL] [Abstract][Full Text] [Related]
13. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
[TBL] [Abstract][Full Text] [Related]
14. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
Smith AL; Skupa SA; Eiken AP; Reznicek TE; Schmitz E; Williams N; Moore DY; D'Angelo CR; Kallam A; Lunning MA; Bociek RG; Vose JM; Mohamed E; Mahr AR; Denton PW; Powell B; Bollag G; Rowley MJ; El-Gamal D
JCI Insight; 2024 May; 9(10):. PubMed ID: 38775157
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
[TBL] [Abstract][Full Text] [Related]
16. AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
Morande PE; Yan XJ; Sepulveda J; Seija N; Marquez ME; Sotelo N; Abreu C; Crispo M; Fernández-Graña G; Rego N; Bois T; Methot SP; Palacios F; Remedi V; Rai KR; Buschiazzo A; Di Noia JM; Navarrete MA; Chiorazzi N; Oppezzo P
Blood; 2021 Jul; 138(3):246-258. PubMed ID: 34292322
[TBL] [Abstract][Full Text] [Related]
17.
Silva Barcelos EC; Rompietti C; Adamo FM; Dorillo E; De Falco F; Del Papa B; Baldoni S; Nogarotto M; Esposito A; Capoccia S; Geraci C; Sorcini D; Stella A; Arcaleni R; Tini V; Imbroisi Valle Errera F; Rosati E; Sportoletti P
Front Oncol; 2023; 13():1218989. PubMed ID: 37817771
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.
Pagano G; Botana IF; Wierz M; Roessner PM; Ioannou N; Zhou X; Al-Hity G; Borne C; Gargiulo E; Gonder S; Qu B; Stamatopoulos B; Ramsay AG; Seiffert M; Largeot A; Moussay E; Paggetti J
Haematologica; 2023 Nov; 108(11):3011-3024. PubMed ID: 37345470
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia.
Goral A; Sledz M; Manda-Handzlik A; Cieloch A; Wojciechowska A; Lachota M; Mroczek A; Demkow U; Zagozdzon R; Matusik K; Wachowska M; Muchowicz A
Exp Hematol Oncol; 2023 Oct; 12(1):89. PubMed ID: 37817276
[TBL] [Abstract][Full Text] [Related]
20. Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.
Merchand-Reyes G; Santhanam R; Valencia-Pena ML; Kumar K; Mo X; Belay T; Woyach JA; Mundy-Bosse B; Tridandapani S; Butchar JP
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]